Oncomed Pharmaceuticals Inc Reaches New 12-Month Low at $13.14 (OMED)
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) hit a new 52-week low on Friday, Stock Ratings Network.com reports. The company traded as low as $13.14 and last traded at $13.40, with a volume of 54,521 shares trading hands. The stock had previously closed at $13.91.
A number of research firms have recently commented on OMED. Analysts at BMO Capital Markets initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “outperform” rating and a $32.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “outperform” rating on the stock. Finally, analysts at Piper Jaffray Cos. initiated coverage on shares of Oncomed Pharmaceuticals in a research note to investors on Monday, August 12th. They set an “overweight” rating and a $19.84 price target on the stock.
Oncomed Pharmaceuticals has a one year low of $15.74 and a one year high of $31.00. The stock’s 50-day moving average is $15.53 and its 200-day moving average is $17.45. The company’s market cap is $369.9 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.81. The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $8.31 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-0.67 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.